1. Home
  2. LMND vs ABCL Comparison

LMND vs ABCL Comparison

Compare LMND & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lemonade Inc.

LMND

Lemonade Inc.

HOLD

Current Price

$53.41

Market Cap

4.2B

Sector

Finance

ML Signal

HOLD

Logo AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

HOLD

Current Price

$11.43

Market Cap

3.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LMND
ABCL
Founded
2015
2012
Country
United States
Canada
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.2B
3.5B
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
LMND
ABCL
Price
$53.41
$11.43
Analyst Decision
Buy
Strong Buy
Analyst Count
7
5
Target Price
$70.86
$8.40
AVG Volume (30 Days)
875.2K
9.0M
Earning Date
04-29-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
21.40
10.91
EPS
N/A
N/A
Revenue
$737,900,000.00
$75,128,000.00
Revenue This Year
$65.20
N/A
Revenue Next Year
$33.31
$21.85
P/E Ratio
N/A
N/A
Revenue Growth
40.15
160.56
52 Week Low
$46.16
$2.75
52 Week High
$99.90
$12.58

Technical Indicators

Market Signals
Indicator
LMND
ABCL
Relative Strength Index (RSI) 52.19 62.32
Support Level $51.57 $3.39
Resistance Level $56.71 $12.58
Average True Range (ATR) 1.96 0.74
MACD 0.56 -0.15
Stochastic Oscillator 78.36 51.17

Price Performance

Historical Comparison
LMND
ABCL

About LMND Lemonade Inc.

Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes. The company is using technology, data, artificial intelligence, contemporary design, and social impact to deliver delightful and affordable insurances. The Company operates in one report segment providing personal property and casualty insurance products within the United States and Europe, including the UK.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Share on Social Networks: